Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes
Open Access
- 15 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (6) , 1913-1920
- https://doi.org/10.1158/1078-0432.ccr-05-1547
Abstract
Purpose: A lipid-based prodrug of mitomycin C [MMC; 2,3-(distearoyloxy)propane-1-dithio-4′-benzyloxycarbonyl-MMC] was designed for liposome formulation. The purpose of this study was to examine the in vitro cytotoxicity, pharmacokinetics, in vivo toxicity, and in vivo antitumor activity of this new lipid-based prodrug formulated in polyethylene glycol–coated (pegylated) liposomes.Keywords
This publication has 35 references indexed in Scilit:
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Macromolecular TherapeuticsClinical Pharmacokinetics, 2003
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Liposomal Drug Carrier Systems in Cancer Chemotherapy: Current Status and Future ProspectsJournal of Drug Targeting, 2002
- Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine ModelsJournal of Drug Targeting, 2002
- The Importance of DT-Diaphorase in Mitomycin C Resistance in Human Colon Cancer Cell LinesJournal of Surgical Research, 1998
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated LiposomesJournal of Liposome Research, 1993
- Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfidesThe Journal of Organic Chemistry, 1990
- Liposomal sustained-release delivery systems for intravenous injection. I. Physicochemical and biological properties of newly synthesized lipophilic derivatives of mitomycin C.CHEMICAL & PHARMACEUTICAL BULLETIN, 1988